Mebendazole - BullFrog AI

Alternative Names: BF-222

Latest Information Update: 03 Apr 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Johns Hopkins University
Developer BullFrog AI; Johns Hopkins University
Class Anthelmintics; Antineoplastics; Benzimidazoles; Carbamates; Small molecules
Mechanism of Action Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

29 Mar 2024 BullFrog AI has patent protection for mebendazole in Europe, France, Japan, India, China, Israel, Switzerland, Italy, Ireland, Germany, Czech Republic, United Kingdom Spain and the USA
29 Mar 2024 Interim adverse events data from a phase I trial in Glioblastoma released byBullFrog AI
14 Dec 2023 BullFrog AI plans a phase II trial in Glioblastoma

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com